Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide alone or with cabergoline in Cushing's disease
NL-OMON42150Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of pasireotide LAR and cabergoline in Corticotropin adenoma (ACTHoma) (2 arms), sponsored by Novartis. Primary endpoint: Proportion of patients with normalized mean urinary free cortisol at week 35. Started May 2015; status: active, not recruiting.
02
Drugs
pasireotide LARcabergoline
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on NL-OMON42150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42150.